Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection : Results of an Italian Compassionate Use Program

Articolo

Data di Pubblicazione:

2017

Citazione:

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection : Results of an Italian Compassionate Use Program / M. Andreoni, E. Teti, A. Antinori, L. Milazzoi, S. Sollima, G. Rizzardini, A. Di Biagio, A. Saracino, R. Bruno, V. Borghi, A. De Luca, A. Cattelan, H. Hasson, G. Taliani, A. Monforte, C. Mastroianni, G. Di Perri, S. Bigoni, M. Puoti, A. Spinetti, A. Gori, N. Boffa, C. Bruno, A. Giacometti, G. Parruti, V. Vullo, A. Chirianni, A. Pennica, C. Pasquazzi, D. Segala, L. Sarmati. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - 64:5(2017), pp. 680-683. [10.1093/cid/ciw846]

Abstract:

Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV)

Tipologia IRIS:

01 - Articolo su periodico

Keywords:

DAA; HIV/HCV co-infection; IFN-free; anti-HCV therapy; antiviral therapy

Elenco autori: